Alemtuzumab 12 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
Alemtuzumab 12 mg may leads to lower number of participants with new T2‐hyperintense lesions on magnetic… compared with interferon beta 1a (low certainty).
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in treament related mortality compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (low certainty).
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in complete response rate compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in treatment related mortality compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to higher complete response rate compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).